SLC5A8 is a conditional tumor suppressor in colon linked to dietary fiber content

SLC5A8 是结肠中的一种条件性肿瘤抑制因子,与膳食纤维含量有关

基本信息

项目摘要

 DESCRIPTION (provided by applicant): LC5A8 was first identified as a candidate tumor suppressor in colon. We showed that it is a Na+-coupled transporter for short-chain fatty acids (SCFAs) and that its ability to energize the cellular entry of the SCFA butyrate, a bacterial fermentation product of dietary fiber and an inhibitor of histone deacetylases, underlies its tumor-suppressive function in colon. However, in vivo studies with Slc5a8-/- mice failed to support such a function. Now we found that the ability of Slc5a8 to protect against colitis and colon cancer is dictated by dietary fiber content. The transporter is obligatory for the beneficial effects of SCFAs in colonic epithelial cells only when the luminal concentrations of SCFAs are low (low fiber intake). In contrast, the obligatory role of the transporter in mucosal immune cells is not dependent on dietary fiber content. We hypothesize that SLC5A8 is a conditional tumor suppressor in colon and is essential for the maintenance of the tolerogenic phenotype of the mucosal immune system, but the obligation of its role in colonic epithelial cells and LP immune cells is differentially influenced by the dietary fiber content. In addition, we hypothesize that SLC5A8 and optimal dietary fiber protect against bacterial dysbiosis in the gut, which is known to drive inflammation and cancer in colon. We will test these hypotheses by completing the following specific aims: (1A) Show that Slc5a8 is essential for the immunotolerant phenotype of the mucosal immune system by qualitatively and quantitatively increasing the number of anti- inflammatory dendritic cells and immunosuppressive Tregs in colon, and determine the relevance of dietary fiber content to this process; (1B) Delineate the phylogenetic profile of gut microbiota in wild type and Slc5a8-/- mice under low-fiber & high-fiber conditions to determine if bacterial dysbiosis occurs in the gut as a consequence of Slc5a8 deletion and/or low dietary fiber, thus driving the increased severity of colitis and enhanced colon cancer observed in Slc5a8-/- mice under low-fiber dietary conditions; (2A) Interrogate the contribution of Slc5a8 in colonic epithelial cells versus Slc5a8 in myeloid cells to the protection against experimental colitis under low-fiber & high-fiber dietary conditions using conditional knockout mice with selective deletion of Slc5a8 either in epithelial cells or in myeloid cells; (2B) Interrogate the contribution of Slc5a8 in colonic epithelial cells versus Slc5a8 in myeloid cells to the protection against experimental colon cancer under low-fiber & high-fiber dietary conditions using conditional knockout mice with selective deletion of Slc5a8 either in epithelial cells or in myeloi cells; (3) Dissect the changes in histone acetylation and consequent transcriptome landscape in colonic epithelial cells and LP dendritic cells that are responsible for the ability of Slc5a8 to protect against colitis and colon cancer under low-fiber & high-fiber dietary conditions.
 描述(由申请人提供):LC 5A 8首次被鉴定为结肠中的候选肿瘤抑制因子。我们发现,它是一个Na+耦合转运短链脂肪酸(SCFAs)和它的能力,激励进入细胞的SCFA丁酸酯,细菌发酵产物的膳食纤维和组蛋白脱乙酰酶的抑制剂,在结肠肿瘤抑制功能的基础。然而,用Slc 5a 8-/-小鼠进行的体内研究未能支持这种功能。现在我们发现Slc 5a 8预防结肠炎和结肠癌的能力取决于膳食纤维含量。运输商是有义务为有益的 只有当SCFA的管腔浓度低(低纤维摄入)时,SCFA才能在结肠上皮细胞中发挥作用。相反,粘膜免疫细胞中转运蛋白的强制性作用 不依赖于膳食纤维的含量。我们假设SLC 5A 8是结肠中的条件性肿瘤抑制因子,并且对于维持粘膜免疫系统的耐受性表型是必不可少的,但是其在结肠上皮细胞和LP免疫细胞中的作用的义务受到膳食纤维含量的差异影响。此外,我们假设SLC 5A 8和最佳膳食纤维可以防止肠道中的细菌生态失调,这是已知的结肠炎症和癌症。(1A)通过定性和定量地增加结肠中抗炎树突状细胞和免疫抑制性T细胞的数量来证明Slc 5a 8对于粘膜免疫系统的免疫耐受表型是必需的,并确定膳食纤维含量与该过程的相关性;(1B)描绘野生型和Slc 5a 8-/-小鼠在低纤维和高纤维条件下的肠道微生物群的系统发育谱,以确定肠道中是否由于Slc 5a 8缺失和/或低膳食纤维而发生细菌生态失调,从而导致在低纤维饮食条件下在Slc 5a 8-/-小鼠中观察到的结肠炎严重程度增加和结肠癌增强;(2A)询问结肠上皮细胞中的Slc 5a 8相对于骨髓细胞中的Slc 5a 8对在低纤维和高纤维条件下针对实验性结肠炎的保护的贡献。(2B)询问结肠上皮细胞中的Slc 5a 8相对于髓样细胞中的Slc 5a 8对保护结肠上皮细胞或髓样细胞中的Slc 5a 8的贡献 在低纤维和高纤维饮食条件下使用在上皮细胞或骨髓细胞中选择性缺失Slc 5a 8的条件性敲除小鼠对抗实验性结肠癌;(3)解剖结肠上皮细胞和LP树突状细胞中组蛋白乙酰化和随之而来的转录组景观的变化,这些变化负责Slc 5a 8在低纤维和低浓度条件下保护结肠炎和结肠癌的能力。高纤维饮食条件。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.
Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis.
  • DOI:
    10.1002/cphy.c170014
  • 发表时间:
    2017-12-12
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Sivaprakasam S;Bhutia YD;Yang S;Ganapathy V
  • 通讯作者:
    Ganapathy V
Gut Microbiome and Colon Cancer: Role of Bacterial Metabolites and Their Molecular Targets in the Host.
  • DOI:
    10.1007/s11888-017-0362-9
  • 发表时间:
    2017-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bhutia YD;Ogura J;Sivaprakasam S;Ganapathy V
  • 通讯作者:
    Ganapathy V
The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data.
妇女健康倡议;
  • DOI:
    10.1002/cncr.33261
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Wachtel,MitchellS
  • 通讯作者:
    Wachtel,MitchellS
SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms.
  • DOI:
    10.1042/bj20150751
  • 发表时间:
    2016-05-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bhutia YD;Babu E;Ramachandran S;Yang S;Thangaraju M;Ganapathy V
  • 通讯作者:
    Ganapathy V
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VADIVEL GANAPATHY其他文献

VADIVEL GANAPATHY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VADIVEL GANAPATHY', 18)}}的其他基金

Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
氨基酸转运蛋白 SLC38A5 作为 TNBC 的药物靶点:用遗传和药理学方法进行评估
  • 批准号:
    10576760
  • 财政年份:
    2022
  • 资助金额:
    $ 33.93万
  • 项目类别:
Retinal Iron Homeostasis in Health and Disease
健康和疾病中的视网膜铁稳态
  • 批准号:
    7889446
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
“饿死肿瘤细胞”:SLC6A14作为结肠癌的药物靶点
  • 批准号:
    8077946
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
Retinal Iron Homeostasis in Health and Disease
健康和疾病中的视网膜铁稳态
  • 批准号:
    8035342
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
Retinal Iron Homeostasis in Health and Disease
健康和疾病中的视网膜铁稳态
  • 批准号:
    8231427
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
“饿死肿瘤细胞”:SLC6A14作为结肠癌的药物靶点
  • 批准号:
    7963106
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
Retinal Iron Homeostasis in Health and Disease
健康和疾病中的视网膜铁稳态
  • 批准号:
    8423033
  • 财政年份:
    2010
  • 资助金额:
    $ 33.93万
  • 项目类别:
Molecular Analysis of a Novel Opioid Peptide Transporter
新型阿片肽转运蛋白的分子分析
  • 批准号:
    7230316
  • 财政年份:
    2006
  • 资助金额:
    $ 33.93万
  • 项目类别:
Molecular Analysis of a Novel Opioid Peptide Transporter
新型阿片肽转运蛋白的分子分析
  • 批准号:
    7127794
  • 财政年份:
    2006
  • 资助金额:
    $ 33.93万
  • 项目类别:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
免疫耐受;
  • 批准号:
    6352379
  • 财政年份:
    2001
  • 资助金额:
    $ 33.93万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 33.93万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了